This is a rare and aggressive type of cancer that starts in the lining of the uterus (endometrium). It affects the connective tissue part of the lining. It can spread quickly to other parts of the body.
Every report comes from a Lived member, sent anonymously.
Have you had Hysterectomy for Endometrial Stromal Sarcoma?
Endometrial stromal sarcoma (ESS) is a rare cancer of the uterus. It starts in the stroma, the supporting tissue of the uterine lining, rather than in the lining's surface cells where the far more common endometrial cancer begins. That difference matters, because ESS is staged, treated and followed differently from endometrial cancer. ESS comes in two main forms. Low-grade ESS is the more common one. It tends to grow slowly, and its cells usually carry receptors for estrogen and progesterone, which means hormones can fuel its growth and hormone-blocking treatment can help control it. High-grade ESS is rarer and more aggressive: most people are diagnosed after it has already spread beyond the uterus, and it usually does not respond to hormone treatment. Knowing which form someone has shapes nearly every later decision. Most people are diagnosed in their 40s or early 50s, and more than half have not yet gone through menopause. The most common symptom is abnormal vaginal bleeding. Others notice pelvic pain or pressure, painful periods or an enlarged uterus, and about one in four has no symptoms at all.
In most people, no cause is found. Researchers have found characteristic gene changes inside the tumor cells, which help pathologists identify ESS, but they do not explain why it develops. A few factors are linked to a higher risk: previous radiation therapy to the pelvis, long-term use of estrogen or tamoxifen (a medicine used to treat or prevent breast cancer that has estrogen-like effects on the uterus), and, in some reports, polycystic ovary syndrome. These are associations. Most people with these exposures never develop ESS, and many people with ESS have none of them.
ESS is hard to recognize before surgery. On ultrasound or MRI it can look much like a fibroid (a common, noncancerous muscle growth) or adenomyosis (uterine lining growing into the muscle wall), and no imaging test or blood marker can confirm it. The diagnosis depends on a pathologist examining tumor tissue under a microscope. Sometimes that tissue comes from a biopsy of the uterine lining or a polyp. Often, though, ESS is discovered only after a hysterectomy or myomectomy (fibroid removal) done for what was thought to be a benign problem. Specialized stains and genetic tests on the tissue help confirm ESS, separate the low-grade from the high-grade form, and show whether the tumor carries hormone receptors. Once ESS is diagnosed, a CT scan of the chest, abdomen and pelvis and often a pelvic MRI check whether it has spread. The stage runs from I (confined to the uterus) to IV (spread into the bladder or rectum, or to distant organs such as the lungs) and is the most important single guide to outlook. If ESS was found after surgery in which the uterus was cut into pieces, imaging is especially important to look for disease left behind.
Because ESS is rare, care at a center experienced in sarcoma or gynecologic cancer is recommended. The main treatment is surgery: a hysterectomy, usually with removal of both ovaries and fallopian tubes. The uterus should be removed intact rather than cut into smaller pieces (morcellation), because breaking up the tumor can spread cancer cells. When disease has spread, surgeons aim to remove all visible tumor, since leaving none behind is linked to better survival. If ESS was found after a fibroid operation or a morcellated hysterectomy, a second operation may be needed. For low-grade ESS, removing the ovaries takes away the main source of estrogen, and keeping them is linked to a higher chance of the cancer returning. Hormone therapy is often added to further deprive the tumor of estrogen. Options include aromatase inhibitors, pills that block the body's remaining estrogen production, and progestins such as megestrol acetate or medroxyprogesterone acetate. Aromatase inhibitors are often preferred because they are usually better tolerated over the years of treatment, typically at least two and up to five. The same drugs are the mainstay when low-grade ESS has spread or returns, and they can control it for long periods. Studies of hormone therapy after surgery are small and retrospective, so its benefit is likely but not precisely known. Tamoxifen and estrogen-containing hormone therapy are avoided because they can stimulate this tumor. Chemotherapy has no proven role in low-grade ESS. High-grade ESS usually lacks hormone receptors, so hormone therapy does not work. For advanced or recurrent disease, treatment uses chemotherapy designed for soft tissue sarcomas, often based on doxorubicin, sometimes combined with ifosfamide. These regimens can shrink tumors but cause substantial side effects, including low blood counts, nausea and fatigue. Whether chemotherapy after complete surgery helps in early-stage high-grade ESS is uncertain; it is generally considered when the tumor was large, fast-dividing or morcellated. Because high-grade ESS is aggressive, it is generally treated with hysterectomy rather than uterus-sparing approaches. Radiation to the pelvis can lower the chance of the cancer returning there but has not been shown to help people live longer, so it is reserved for selected situations or to relieve symptoms. For a young person with low-grade ESS who wants to become pregnant, keeping the uterus and using hormone treatment has been tried at specialist centers; pregnancies have been reported, but more than half of these cancers come back, so hysterectomy is usually advised once childbearing is complete. Clinical trials, including of targeted drugs and immunotherapy, are an option for some people.
The outlook depends mostly on the grade and the stage. Low-grade ESS usually behaves slowly: when it is confined to the uterus or pelvis (stage I or II), more than 90 percent of people are alive five years later, and about half are with stage III or IV disease. Even when it returns, it can often be controlled for years with surgery and hormone treatment. High-grade ESS is more serious. It tends to come back sooner, often within the first year, and outcomes are poorer, especially when it has already spread at diagnosis. After treatment, follow-up involves regular visits, pelvic examinations and periodic scans, because ESS can return in the pelvis, abdomen, vagina or lungs. Low-grade ESS is known for coming back many years after the first operation, so follow-up continues long term rather than stopping after five years. For people who were premenopausal, removing the ovaries brings on menopause immediately, with hot flashes, sleep changes and vaginal dryness. The usual estrogen replacement is generally avoided after low-grade ESS, so managing these symptoms without estrogen is a common part of long-term care. Aromatase inhibitors can cause joint aches and gradual bone thinning, so bone health is often monitored. Because ESS is uncommon, people often find it helpful to connect with sarcoma or gynecologic cancer support networks.
Arrange an appointment for abnormal vaginal bleeding, especially any bleeding after menopause or while taking tamoxifen, or for pelvic pain, pressure or a uterus that seems to be growing. If a fibroid or hysterectomy operation unexpectedly shows ESS, ask for a prompt referral to a gynecologic oncologist or sarcoma specialist before any further treatment. After treatment, contact your care team soon about new vaginal bleeding, new pelvic or abdominal pain or swelling, or a cough or breathlessness that does not settle, since these can be early signs that the cancer has returned.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Endometrial Stromal Sarcoma is like, what's helped you, or ask the community a question.